Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

Acute Inflammation I: Inflammatory Response

Acute Inflammation I: Inflammatory Response

Acute inflammation is a rapid, short-lived physiological response to tissue injury or infection, designed to eliminate harmful agents and initiate repair. This tightly regulated process typically lasts from minutes to several days and is triggered by factors such as microbial invasion, physical trauma, or chemical injury.Recognition and Mediator ReleaseThe inflammatory response begins when resident immune cells—such as mast cells, macrophages, and dendritic cells—detect damage-associated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203.

Leukemia·2025

Same author

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms.

Leukemia·2023

Same author

Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants.

Blood cancer journal·2021

Same author

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.

Blood·2021

Same author

Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2021

Same author

Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2021

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Response in acute myeloid leukemia.

¹Division of Hematology, University of Washington Medical Center, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA 98109, USA. eestey@u.washington.edu

Clinical Advances in Hematology & Oncology : H&O

|March 19, 2008

Summary

This study examines survival outcomes for acute myeloid leukemia patients achieving responses beyond complete remission (CR). It highlights the importance of evaluating less stringent responses, like CRp, for patient survival benefits.

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Related Experiment Videos

Last Updated: Jul 6, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Area of Science:

Hematology
Oncology
Clinical Trials

Background:

Historically, complete response (CR) was the sole benchmark for induction therapy in acute myeloid leukemia (AML).
Patient survival has been the primary outcome of interest, driving the focus on CR.
Recent advancements acknowledge responses like complete response with incomplete platelet recovery (CRp) as indicators of drug activity.

Purpose of the Study:

To investigate the survival impact of non-CR responses in acute myeloid leukemia patients.
To evaluate the clinical significance of responses less stringent than CR, such as CRp.
To provide a comprehensive understanding of treatment efficacy beyond traditional CR metrics.

Main Methods:

Review of clinical data and patient outcomes from induction therapy trials in AML.
Analysis of survival data stratified by different response categories (CR, CRp, etc.).
Comparative assessment of survival rates across various response milestones.

Main Results:

Complete response (CR) in AML has historically correlated with improved survival.
Emerging data suggests that responses like CRp, while not CR, may also be associated with meaningful survival benefits.
Further research is needed to fully elucidate the survival advantage conferred by these less stringent responses.

Conclusions:

The definition of successful AML induction therapy is evolving beyond CR.
Responses like CRp indicate therapeutic activity and warrant further investigation for their survival implications.
A broader assessment of treatment response is crucial for optimizing AML patient care and outcomes.